KZIA
NASD Kazia Therapeutics Ltd Sponsored ADR$7.40 ↑ +0.15 (+2.07%) Trading Up from the previous close of $7.25, $0.39 below the day’s high of $7.79
- YTD change
- +7.40%
- vs 20-day SMA
- -20.12%
- vs 200-day SMA
- -29.22%
Price ranges
Price & Performance
-3.52 (-32.23%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 99.1% away from all-time highs of $792.50
- KZIA is up 7% since the beginning of the year
- KZIA is up 6% over the past 12 months
- KZIA is down 32% over the past 1 month
- 7% of all KZIA investors are betting against KZIA
KZIA reads not so good: price sits below both the 20- and 200-day averages, the 12-month move is +5.9%.
- Previous minute
- +$0.00
- Last hour
- -$0.10
- Last 5 days
- -16.10%
- vs 8-day SMA
- -12.09%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Kazia Therapeutics Ltd. is an oncology-focused biotechnology company, which engages in the business of pharmaceutical drug development. It focuses on its Paxalisib program, which is designed to treat brain cancer. The company was founded by Graham Edmund Kelly in March 1994 and is headquartered in Sydney, Australia.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.